S. V Rajkumar
ECOG-ACRIN Cancer Research Group · Mayo Clinic
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name S. V Rajkumar as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:31 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT00098475 · Lenalidomide and Dexamethasone With or Without Thalidomide in Treating Patients With Multiple MyelomaNational Cancer Institute (NCI) · active not recruiting · DS Stage I Multiple Myeloma, DS Stage II Multiple Myeloma, DS Stage III Multiple Myeloma · principal investigator
- Ph3NCT00033332 · Dexamethasone With or Without Thalidomide in Treating Patients With Newly Diagnosed Multiple MyelomaNational Cancer Institute (NCI) · completed · Multiple Myeloma and Plasma Cell Neoplasm · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-12 11:31 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Onset and biomarkers for progression of monoclonal gammopathiesR01CA168762 · NCI · MAYO CLINIC ROCHESTER · fiscal years 2012 to 2024 · $78,948 awarded in 2024Same name and institution; not confirmed by an ID
- Prevalence and Progression of Monoclonal GammopathiesR01CA107476 · NCI · MAYO CLINIC ROCHESTER · fiscal years 2004 to 2018 · $321,975 awarded in 2018Same name and institution; not confirmed by an ID
- Epidemiology of MGUS in Southeastern MinnesotaP01CA062242 · NCI · MAYO CLINIC ROCHESTER · fiscal years 2005 to 2009 · $261,778 awarded in 2009Same name and institution; not confirmed by an ID
- Treatment of Early Stage Multiple MyelomaR01CA100080 · NCI · MAYO CLINIC ROCHESTER · fiscal years 2003 to 2006 · $257,207 awarded in 2006Same name and institution; not confirmed by an ID
- Angiogenesis and thalidomide therapy in multiple myelomaR01CA093842 · NCI · MAYO CLINIC ROCHESTER · fiscal years 2002 to 2004 · $279,135 awarded in 2004Same name and institution; not confirmed by an ID
- ANGIOGENESIS AND ANGIOGENIC CYTOKINES IN MYELOMAR21CA085818 · NCI · MAYO CLINIC ROCHESTER · fiscal years 2000 to 2001 · $141,100 awarded in 2001Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- ECOG-ACRIN Network Group Operations CenterU10CA180820 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI Peter J ODwyer, MITCHELL D. SCHNALL · fiscal years 2014 to 2026Named on NCT00098475
- Eastern Cooperative Oncology Group Operations OfficeU10CA021115 · NCI · FRONTIER SCI & TECHNOLOGY RSCH FDN, INC · PI ROBERT L COMIS · fiscal years 1985 to 2013Named on NCT00098475, NCT00033332
Most cited trial papers
Clinical-trial papers with this author name in multiple myeloma, ranked by citations from NIH iCite, fetched 2026-11-12 11:31 UTC. The ranking covers the 200 most relevant of 89 PubMed records, and a shared surname and initials can bring in a namesake. All 89 on PubMed
- A phase 2 study of bortezomib in relapsed, refractory myeloma.N Engl J Med · 20032,213 citationsRCR 42.2
- Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.N Engl J Med · 20151,133 citationsRCR 36.3
- 1,038 citationsRCR 22.6
- 827 citationsRCR 21.0
- 773 citationsRCR 27.7
- 691 citationsRCR 15.1
- 536 citationsRCR 19.7
- Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma.Blood · 2005518 citationsRCR 10.6
- Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib.J Clin Oncol · 2006502 citationsRCR 11.8
- 422 citationsRCR 9.6